Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy

Researchers published in The New England Journal of Medicine results of

Read the full 115 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE